Clinical Trial Update: Exploring the Efficacy and Safety of CS20AT04 (Allogenic Bone Marrow-Derived Stem Cell) in Systemic Lupus Erythematosus Patients [Phase 2]

View source ↗

Summary

Phase 2 clinical trial updating the efficacy and safety of CS20AT04 (allogeneic bone marrow-derived stem cell) in patients with systemic lupus erythematosus. St…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Systemic Lupus Erythematosus

Drugs mentioned

• CS20AT04

Snippet

Sponsor: Hanyang University Seoul Hospital | Conditions: Systemic Lupus Erythematosus | Phase 2 | Status: UNKNOWN